A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy, Safety and Immunogenicity of Recombinant Zoster Vaccine (CHO Cell) in Adults Aged 40 Years and Above
Latest Information Update: 28 Oct 2024
At a glance
- Drugs Herpes zoster vaccine MAXVAX Biotechnology (Primary)
- Indications Herpes zoster
- Focus Adverse reactions; Registrational
- Sponsors MAXVAX Biotechnology
- 24 Oct 2024 Status changed from not yet recruiting to active, no longer recruiting.
- 12 Jun 2024 New trial record